Executive Summary
Healthcare in Africa is undergoing a demand transformation and a supply transformation at the same time.
Population growth, urbanization, infectious diseases, noncommunicable diseases, maternal and child health requirements and wider universal health coverage are increasing demand for medicines, diagnostics, hospitals, devices and healthcare services.
Governments are simultaneously working to reduce import dependence and build regional health-product industries. The strongest long-term strategy for Pakistan therefore moves beyond one-off exports:
Export -> Registration -> Distribution -> Institutional Procurement -> Local Partnerships -> Contract Manufacturing -> Joint Ventures -> Regional Production
Why African Healthcare Demand Is Growing
Africa carries a large communicable-disease burden alongside a rapidly expanding noncommunicable-disease challenge. WHO estimates that the African Region accounted for approximately 265 million malaria cases and 579,000 deaths in 2024. Around 26.3 million people were living with HIV, while noncommunicable diseases already account for roughly 37% of deaths in the Region.
Infectious Disease
Antimalarials, rapid diagnostics, laboratory products, antiretroviral medicines, TB products and supply-chain solutions.
Chronic Disease
Cardiovascular, hypertension, diabetes, cancer, kidney, respiratory and mental-health products.
Maternal & Child Health
Essential medicines, diagnostics, supplements, reproductive-health products and hospital supplies.
Health Workforce
Telemedicine, clinical decision support, training platforms, laboratory systems and remote diagnostics.
Affordability Is as Important as Demand
More than 423 million people in Africa experienced financial hardship from out-of-pocket healthcare spending in 2022. The commercial opportunity therefore depends on quality-assured affordability, efficient distribution and products suited to public and household purchasing power.
Africa Is Moving Toward Pharmaceutical Self-Reliance
WHO's 2025-2035 framework states that countries in its African Region import 70-100% of finished pharmaceutical products, about 99% of vaccines and 90-100% of medical devices and active pharmaceutical ingredients. Approximately 649 pharmaceutical plants were identified across 29 countries.
African leaders have reaffirmed an objective of meeting at least 60% of continental health-product requirements through local manufacturing by 2040, covering pharmaceuticals, vaccines, diagnostics and medical devices.
Partnership Models for Pakistani Companies
Local production can reduce shipping costs, improve tender eligibility and deepen government and institutional relationships, but it must be supported by demand, financing, utilities, workforce, quality systems and predictable procurement.
Pooled Procurement, Regulatory Harmonization and WHO Prequalification
African Pooled Procurement Mechanism
The Africa CDC-led APPM aggregates demand across African Union member states to improve purchasing power, product availability, supply-chain resilience and market shaping while supporting capable African manufacturers.
African Medicines Agency
AMA is intended to strengthen continental regulatory capacity and build on the African Medicines Regulatory Harmonization programme. Its operations began in Kigali following appointment of the inaugural Director General, although national marketing authorization remains essential.
WHO Prequalification
WHO prequalification assesses eligible medicines, vaccines, diagnostics and other health products against international standards. More than 1,700 health products were listed by the end of 2025. For manufacturers, qualification can support donor tenders, government procurement, reliance-based registration and wider market credibility.
Where Pakistan Already Has a Competitive Base
Pakistan's pharmaceutical exports increased 34.2% to US$458 million in FY2024-25. The State Bank of Pakistan linked part of that growth to improved access under the Engage Africa Policy, including Congo, Ghana, Djibouti and Sudan.
Pakistan also exported approximately US$445 million of surgical goods and medical instruments in FY2023-24. Sialkot's established cluster produces precision instruments including forceps, scissors, scalpels and clamps.
| Opportunity | Potential Pakistani Offering |
|---|---|
| Essential Medicines | Affordable branded and unbranded generics |
| NCD Medicines | Cardiovascular, hypertension, diabetes and chronic-disease products |
| Hospital Products | Injectables, IV products, consumables and institutional formulations |
| Surgical Instruments | Forceps, scissors, clamps, scalpels and precision instruments |
| Diagnostics | IVDs and diagnostic products meeting destination standards |
| Contract Manufacturing | Production for African brands and distributors |
| Healthcare IT | Hospital systems, telemedicine, laboratory and digital-health platforms |
| Supply Chain | Warehousing, pharmaceutical logistics and cold-chain partnerships |
African Markets to Prioritize
Kenya
East African manufacturing and distribution hub with a formal market-authorization pathway through the Pharmacy and Poisons Board.
Nigeria
Large-scale market with NAFDAC requirements for imported medicines, devices, GMP and CTD dossiers.
South Africa
Sophisticated market regulated by SAHPRA with demanding marketing-authorization and licensing standards.
Egypt
Major manufacturing base with detailed EDA registration, bioequivalence, API and pharmacovigilance guidance.
Ghana & Tanzania
Important domestic and regional markets with established medicine-registration authorities.
Rwanda & Ethiopia
Transparent regulatory gateways with digital or published product-registration processes.
Country selection should reflect product-market fit, disease burden, pricing, competition, reimbursement, registration cost, distributor quality and institutional procurement channels.
Standard Pharmaceutical Market-Entry Process
- Select market and product portfolioEvaluate demand, margins, competition and registration economics.
- Review regulatory eligibilityConfirm GMP, country-of-origin registration, WHO PQ and product restrictions.
- Appoint a local representativeWhere required, select a technically competent and commercially credible local agent.
- Prepare the CTD/eCTD dossierCompile quality, safety, efficacy, stability, labelling, CPP, CoA and bioequivalence evidence.
- Complete assessment and GMP verificationRespond to regulator questions and inspections.
- Obtain marketing authorizationDo not ship commercial product before the applicable approvals.
- License importer and distributorConfirm import permissions, warehousing, cold chain and pharmacovigilance.
- Build institutional salesMonitor public tenders, hospitals, donor procurement and APPM opportunities.
Pakistan's Own Regulatory Readiness
Export growth depends on international confidence in Pakistani manufacturing and regulation. Companies should maintain DRAP registration, current GMP compliance, stability evidence, validated quality systems, documentation integrity and export permissions.
Vaccines, Medical Devices, Digital Health and Supply Chains
Vaccines
Gavi's African Vaccine Manufacturing Accelerator can make up to US$1.2 billion available over ten years to support commercially viable African manufacturing.
Medical Devices
Pakistan can build on surgical-instrument capability through certification, traceability, sterile packaging, distributor training and after-sales support.
Digital Health
Hospital information systems, telemedicine, laboratory platforms, pharmacy systems, health analytics and BPO can address workforce and access constraints.
Logistics & Cold Chain
Distributor due diligence must verify warehousing, temperature control, inventory management, traceability, recall capability and last-mile reach.
Manufacturing Finance
Projects may combine sponsor equity, African investors, development finance, blended capital, government incentives and procurement commitments.
Key Risks and the 2026-2035 Outlook
Regulatory Delay
Model realistic registration timelines and maintain complete, responsive dossiers.
Quality & Compliance
Strengthen GMP, pharmacovigilance, traceability, recalls and post-market surveillance.
Distributor Risk
Verify licences, ownership, storage, sales reach, financial capacity and institutional relationships.
Price & Payment Risk
Assess tender pricing, FX, reimbursement, payment cycles and trade-finance needs.
Supply-Chain Risk
Build inventory, cold-chain, alternate routes and continuity plans.
Policy & Localization
Anticipate local-content preferences, technology transfer and changing procurement rules.
Five Strategic Transitions
- From export-only to local presenceBuild durable registration, representation and distribution.
- From distributor dependence to verified partnershipsMeasure operational capability, not promises.
- From single-country sales to regional strategiesUse hubs while respecting national authorization.
- From generic volume to qualified procurementTarget WHO PQ and institutional channels selectively.
- From supplier to healthcare partnerCombine products with technology, training and local production.
PAEC Perspective
Pakistan Should Move from Pharmaceutical Exporter to Healthcare Partner
PAEC can help companies progress from market research to regulatory partner identification, distributor verification, institutional introductions, tender intelligence, manufacturing partnerships and local representation.
Key Takeaways
Africa needs affordable, quality healthcare products while building local manufacturing. Pakistan can contribute most effectively through regulatory compliance, technology transfer, local partnerships and long-term commercial presence.
Data & Methodology Note
This report draws primarily on official information from WHO, Africa CDC, the African Union, Gavi, the Global Fund, African medicines regulators, the State Bank of Pakistan, Pakistan Bureau of Statistics, TDAP and DRAP. Disease-burden statistics generally refer to 2024 data published during 2025-2026; Pakistan trade figures use fiscal years.
Official links were reviewed on 28 August 2026. Manufacturing conditions, tender rules and regulatory requirements change. This report provides market intelligence and commercial guidance, not medical, regulatory or legal advice. Every product must be assessed against the current requirements of the destination-country regulator.
Important Reports, Policies & Official Reading
- WHO - Africa Local Manufacturing Framework 2025-2035Import dependence and the regional local-production framework.
- Africa CDC - African Pooled Procurement MechanismContinental demand aggregation, supplier engagement and market shaping.
- African Union - African Medicines AgencyTreaty status and operationalization of the continental regulator.
- WHO - Prequalification of Health ProductsQuality, safety, efficacy and international-procurement pathway.
- WHO - World Malaria Report 2025Official 2024 malaria burden and regional trends.
- Gavi - African Vaccine Manufacturing AcceleratorFinancing mechanism for commercially viable African vaccine manufacturing.
- Global Fund - Quality AssuranceSupplier quality requirements for pharmaceuticals, devices and diagnostics.
- State Bank of Pakistan - Annual Report 2024-25Pakistan pharmaceutical exports and African market-access growth.
- Pakistan Bureau of Statistics - External Trade FY2023-24Surgical goods and medical-instrument exports.
- TDAP - PharmaceuticalsPakistan pharmaceutical export strategy and African target markets.
- DRAP - Pharmaceutical GuidelinesRegistration, CTD, manufacturing and quality guidance.
- Kenya Pharmacy and Poisons Board - Market AuthorisationOfficial Kenyan health-product registration pathway.
- NAFDAC - Imported Drug RegistrationOfficial Nigerian requirements for imported drug products.
- SAHPRA - Licences and PermitsSouth African manufacturing, import, export and distribution licensing.
- Egyptian Drug Authority - Regulatory GuidelinesOfficial pharmaceutical-product regulatory guidance.